Surfix Diagnostics appoints Jos Lunenberg as its new Chief Executive Officer

Last week, on August 1st, Jos Lunenberg , a seasoned Life Sciences industry executive and Health-tech business owner, strengthened the team of Surfix Diagnostics as Managing Director and CEO of Surfix Diagnostics.

Surfix's photonic biosensor platform can serve many different applications within and even outside Life Sciences. However, as focus is key for a rapidly growing startup organization one specific application has been chosen earlier this year to move full speed ahead on; a platform for oncology diagnostics. "For some very good reasons," comments founder and CTO, Luc Scheres. "The highly promising results of some customer projects tailored to biomarker detection in liquid biopsies of solid tumours, the potential significant positive impact for cancer patients and the size and high pace at which the liquid biopsy market is growing, made this a very logical choice."

The appointment of Jos emphasizes the new strategy direction of the company. He brings over 30 years of experience and proven success in the Life Sciences industry, excelling in entrepreneurship, marketing strategy, fundraising and business management. Before becoming a business owner, Jos was a member of the executive management teams at CERUS Europe BV (NASDAQ: CERS) and Cryo-Save NV (Euronext: CRYO) and Global Marketing Director at Organon NV. He successfully commercialized new pharmaceutical, diagnostic and other Life Sciences products. Jos obtained an MBA at the New York Institute of Technology and a Master's in Medical Biology at the University of Groningen.

In the last six years before joining Surfix Diagnostics he founded and led ENPICOM, a biomedical software company. Under his leadership, ENPICOM raised three consecutive investment rounds, got eight subsidy and two innovation loan applications granted, grew the team to over 40 members, professionalized all departments, obtained an ISO27001 certification, identified an excellent product-market fit for its ImmunoGenomiX (IGX) SaaS platform in Antibody Discovery and generated recurring revenues from CRO's and biotech SMEs to top 25 big pharmaceutical companies.

The freshly appointed CEO remarks: "After founding ENPICOM and leading the company from early start-up to the scale up phase, I felt it was time for new professional challenge in a start-up environment. The common thread in my career has been oncology and innovation. At Surfix Diagnostics highly innovative solution is developed by a team of professionals with the same passion for healthcare innovations as I have and my first week felt as a warm bath. I look very much forward to guiding the company to success in this exciting market and saving a lot of lives of cancer patients as a result."

"We are extremely pleased to add Jos to our team as our new Chief Executive Officer. He has a great international track record in the Life Sciences industry, and brings very relevant market, business and entrepreneurial experience to our company to further grow the business in the coming years" concluded Luc Scheres.

Surfix Diagnostics
Agro Businesspark 2
6708 PW Wageningen
The Netherlands
+31 85 488 1285
info@surfixdx.com

Surfix Diagnostics is a Dutch diagnostics technology company founded in 2011 and headquartered in Wageningen. Surfix develops lab-on-a-chip solutions for early detection and monitoring of solid tumours in liquid biopsies, utilizing its photonic diagnostics platform that combines six state-of-the-art technologies. The platform is so versatile that it can be used for immunoassays AND for molecular diagnostics. Any protein or nucleic acid-based biomarker in a liquid biopsy can be detected, provided a suitable bioreceptor to capture this biomarker is available.

The core of Surfix's diagnostics platform is a photonic biochip, which is integrated into a microfluidic cartridge, both optimized with Surfix's proprietary nanocoatings. The biosensor cartridge is used in combination with a dedicated desktop reader.

This release was published on openPR.